Moderna Inc. Company Profile
NASDAQ: MRNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Moderna at a glance
Moderna Inc. (NASDAQ: MRNA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Cambridge, MA. Moderna is led by Mr. Stéphane Bancel M.B.A. and employs about 4,700 people. The company's shares have traded publicly since 2018.
At a market capitalization of $78.44 billion, it is considered a large-cap company. MRNA is a member of the SP500. Its SEC Central Index Key (CIK) is 0001682852, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Moderna do?
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Moderna Inc.
- Ticker
- NASDAQ: MRNA
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Stéphane Bancel M.B.A.
- Employees
- 4,700
- Headquarters
- 325 Binney Street, Cambridge, MA, United States
- Phone
- 617 714 6500
- Website
- modernatx.com
- IPO year
- 2018
- Market cap
- $78.44B
- SEC CIK
- 0001682852
- Latest annual report
- 10-K · Feb 20, 2026
Index membership
Companies similar to Moderna
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RVMDRevolution Medicines Inc. | 188.12 | -6.35% | $40.32B | vs MRNA |
| BIIBBiogen Inc. | 218.43 | -1.67% | $32.27B | vs MRNA |
| BNTXBioNTech SE ADR | 92.06 | -3.35% | $23.13B | vs MRNA |
| EXELExelixis Inc. | 59.02 | +0.99% | $14.62B | vs MRNA |
| NBIXNeurocrine Biosciences Inc. | 141.25 | -1.55% | $14.36B | vs MRNA |
| HALOHalozyme Therapeutics Inc. | 109.84 | -0.86% | $12.47B | vs MRNA |
| TECHBio-Techne Corp | 72.45 | -0.11% | $11.36B | vs MRNA |
| IBRXImmunityBio Inc. | 9.91 | +1.64% | $10.50B | vs MRNA |